Cannabis has had a long, difficult and often contradictory relationship with the pharmaceutical world but it is making something of a resurgence and the companies that specialize in it are full of confidence for the future.
Used as a medicine as far back as 3,000 years ago, it ended up on the narcotics list in the 1950s and by the 1970s was lumped with heroin, LSD, mescaline and GHB as a Schedule One drug under the US Controlled Substances Act.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze